Bioventus’ (BVS) “Overweight” Rating Reiterated at Cantor Fitzgerald

Bioventus (NASDAQ:BVS)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 5.19% from the company’s current price.

BVS has been the topic of several other reports. Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 6th. Craig Hallum reaffirmed a “buy” rating and issued a $18.00 price target on shares of Bioventus in a report on Thursday, August 6th. Barrington Research set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Bioventus in a research report on Tuesday, June 16th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Bioventus currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Bioventus Stock Performance

Shares of NASDAQ:BVS opened at $14.26 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 1.82 and a beta of 0.63. The firm has a 50 day moving average of $11.36 and a 200 day moving average of $9.91. Bioventus has a 52 week low of $6.26 and a 52 week high of $15.89.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. The firm had revenue of $153.21 million during the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, sell-side analysts predict that Bioventus will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

A number of hedge funds have recently modified their holdings of BVS. Marshall Wace LLP lifted its position in shares of Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after buying an additional 1,887 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP boosted its position in Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after acquiring an additional 3,909 shares during the last quarter. Hedge funds and other institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.